GlassScriptPhysician profile
Emily Kastner
NPI 1629563200
$2,349.64
in general payments reported to CMS, 2019-2025
21 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $179 · 2022: $317 · 2023: $600 · 2024: $793 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,853.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $457.50 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $327.91 | 2021-2024 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $280.88 | 2021-2024 | Lifevest |
| Pfizer INC. | $201.94 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $169.12 | 2022-2023 | Xarelto |
| Amgen INC. | $125.48 | 2022-2024 | Repatha |
| Alnylam Pharmaceuticals INC. | $116.77 | 2023-2025 | Onpattro, Amvuttra |
| Novartis Pharmaceuticals Corporation | $113.03 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $101.40 | 2023-2024 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.26 | 2023-2025 | Jardiance |
| Daiichi Sankyo INC. | $52.29 | 2024 | Injectafer |
| Edwards Lifesciences Corporation | $50.29 | 2023-2024 | |
| Bridgebio Pharma, INC. | $45.98 | 2025 | Attruby |
| Regeneron Healthcare Solutions, INC. | $44.52 | 2023-2024 | Evkeeza |
| Philips North America LLC | $41.78 | 2025 | Ecc Solutions, Mcot |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $35.35 | 2025 | |
| Sanofi-Aventis U.S. LLC | $30.35 | 2024 | |
| Inspire Medical Systems, INC. | $21.08 | 2024 | Inspire |
| Kiniksa Pharmaceuticals International, Plc | $18.04 | 2024 | Arcalyst |
| Medtronic, INC. | $16.07 | 2025 | Symplicity G3 |
| Boston Scientific Corporation | $14.60 | 2023 | Vigilant X4 Crt-D |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Kastner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.